Glaukos Corporation (NYSE:GKOS) Q1 2026 Earnings Call Transcript
Glaukos Corporation (NYSE:GKOS) Q1 2026 Earnings Call Transcript April 29, 2026Glaukos Corporation beats earnings expectations. Reported EPS is $-0.18, expectations were $-0.3.
Glaukos Corp (GKOS)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Millennium Management Israel Englander | 1,581,016 | $220,962,796 | +35% | 0.08% |
| 2. | Holocene Advisors Brandon Haley | 1,514,931 | $211,726,757 | +10% | 0.48% |
| 3. | Citadel Investment Group Ken Griffin | 1,390,017 | $194,268,776 | -4% | 0.02% |
| 4. | Driehaus Capital Richard Driehaus | 650,571 | $90,923,803 | +34% | 0.53% |
| 5. | Braidwell LP Alex Karnal | 591,927 | $82,727,718 | -23% | 3.06% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $23.84 | 2,100 | $50,064.00 | 102,100 | 2017-11-22 | Filing | |
| $16.03 | 2,500 | $40,075.00 | 5,000 | 2016-03-04 | Filing | |
| $15.30 | 1,388 | $21,236.40 | 1,388 | 2015-12-31 | Filing | |
| $15.30 | 1,388 | $21,236.40 | 4,656 | 2015-12-31 | Filing | |
| $21.83 | 2,500 | $54,575.00 | 2,500 | 2015-11-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $154.88 | 1,083 | $167,735.04 | 70,818 | 2026-09-25 | Filing | |
| $154.24 | 229 | $35,320.96 | 71,901 | 2026-09-25 | Filing | |
| $152.71 | 136 | $20,768.56 | 72,130 | 2026-09-25 | Filing | |
| $151.70 | 167 | $25,333.90 | 72,266 | 2026-09-25 | Filing | |
| $172.00 | 4 | $688.00 | 72,433 | 2026-09-16 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 84 | $13,792 | 0% | |
| 2. | 6 | $985 | 0% | |
| 3. | 0 | $0 | 0% |
News See All
Strong Results with 38.1% Revenue Growth Lifted Glaukos (GKOS) in Q4
Brown Capital Management, an investment management company, released its fourth quarter 2025 investor letter for “The Brown Capital Management Small Company Fund”.
Glaukos Corporation (NYSE:GKOS) Q4 2025 Earnings Call Transcript
Glaukos Corporation (NYSE:GKOS) Q4 2025 Earnings Call Transcript February 17, 2026Glaukos Corporation misses on earnings expectations. Reported EPS is $-0.28 EPS, expectations were $-0.22.
What Makes Glaukos (GKOS) a Good Investment?
Fred Alger Management, an investment management company, released its “Alger Weatherbie Specialized Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Glaukos Corporation (NYSE:GKOS) Q3 2025 Earnings Call Transcript
Glaukos Corporation (NYSE:GKOS) Q3 2025 Earnings Call Transcript October 30, 2025 Operator: Ladies and gentlemen, thank you for standing by.
Glaukos Corporation (GKOS) Eye Treatment Epioxa Poised for Strong Market Uptake, Says Stifel
Glaukos Corporation (NYSE:GKOS) ranks among the best medical device stocks to invest in.
12 Best Medical Device Stocks to Invest In Now
In this article, we will take a look at the 12 Best Medical Device Stocks to Invest In Now.
Glaukos Corporation (GKOS) Advances Next-Gen Glaucoma and Corneal Therapies, Eyes FDA Approval for Epioxa
In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Glaukos Corporation stands seventh among them.
13 Most Oversold Healthcare Stocks So Far in 2025
In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025.
Glaukos Corporation (NYSE:GKOS) Q2 2025 Earnings Call Transcript
Glaukos Corporation (NYSE:GKOS) Q2 2025 Earnings Call Transcript July 31, 2025 Operator: Welcome to Glaukos Corporation's Second Quarter 2025 Financial Results Conference Call.